| Literature DB >> 25741241 |
Tamara M Stawicki1, Robert Esterberg2, Dale W Hailey1, David W Raible1, Edwin W Rubel2.
Abstract
The majority of hearing loss and balance disorders are caused by the permanent loss of mechanosensory hair cells of the inner ear. Identification of genes and compounds that modulate susceptibility to hair cell death is frequently confounded by the difficulties of assaying for such complex phenomena in mammalian models. The zebrafish has emerged as a powerful animal model for genetic and chemical screening in many contexts. Several characteristics of the zebrafish, such as its small size and external location of mechanosensory hair cells within the lateral line sensory organ, uniquely position it as an ideal model organism for the study of hair cell toxicity. We have used this model to screen for genes and compounds that affect hair cell survival during ototoxin exposure and have identified agents that would not be expected to play a role in this process based on a priori knowledge of their function. The identification of such agents yields better understanding of hair cell death and holds promise to stem hearing loss and balance disorders in the human population.Entities:
Keywords: aminoglycoside; chemical genetics; cisplatin; hair cell; lateral line; mechanotransduction; ototoxicity; zebrafish
Year: 2015 PMID: 25741241 PMCID: PMC4332341 DOI: 10.3389/fncel.2015.00046
Source DB: PubMed Journal: Front Cell Neurosci ISSN: 1662-5102 Impact factor: 5.505
Otoprotective compounds identified through chemical screens.
| Protective drug | Protects against | Ototoxins tested | Function (if known) | Reference |
|---|---|---|---|---|
| Amodiaquine$ | G, N | G, N | Histamine N-methyltransferase inhibitor | Ou et al. ( |
| Amsacrine$ | G, N | G, N | Topoisomerase 2 poison | Ou et al. ( |
| Benzamil | C, G, K, N | C, G, K, N | Na+/Ca2+ channel blocker | Vlasits et al. ( |
| Carvedilol | N | N | Beta-2 adrenergic blocker | Ou et al. ( |
| Cepharanthine | N | N | Anti-inflammatory | Ou et al. ( |
| Chloroquine$ | G, N | G, N | Inhibits SLC19A3 | Ou et al. ( |
| Cinchonidine$ | G, N | G, N | - | Ou et al. ( |
| Cinchonine$ | G, N | G, N | - | Ou et al. ( |
| Drofenine | N | N | Acetylcholinesterase inhibitor | Ou et al. ( |
| Fluoxetine | G (st), N | C, G, K, N | Selective serotonin reuptake inhibitor | Vlasits et al. ( |
| Fluspirilene | G (st), N | C, G, K, N | Dopamine antagonist | Vlasits et al. ( |
| Hexamethyleneamiloride | N | N | Na+/H+ antiport inhibitor | Ou et al. ( |
| Loperamide | G, K, N | C, G, K, N | μ-opioid receptor agonist | Vlasits et al. ( |
| Mefloquine$ | G, N | G, N | Inhibitor of histamine-N-methyl transferase | Ou et al. ( |
| Methiothepin | G, N | C, G, K, N | Serotonin and dopamine agonist | Vlasits et al. ( |
| Paroxetine | C, G, N | C, G, K, N | Selective serotonin reuptake inhibitor | Vlasits et al. ( |
| Phenoxybenzamine | G, N | C, G, K, N | Alpha-1 adrenergic blocker | Ou et al. ( |
| PROTO-1 | N | C, N | - | Owens et al. ( |
| PROTO-2 | N | N | - | Owens et al. ( |
| Quinine$ | G, N | G, N | - | Ou et al. ( |
| Ractopamine | G, N, K | C, G, K, N | Beta-adrenergic agonist | Vlasits et al. ( |
| Raloxifene | G, N | C, G, K, N | Estrogen receptor modulator | Vlasits et al. ( |
| Tacrine | N | N | Acetylcholinesterase inhibitor | Ou et al. ( |
| Tamoxifen | G (st), N | C, G, K, N | Estrogen receptor modulator | Vlasits et al. ( |
C = Cisplatin, G = Gentamicin, K = Kanamycin, N = Neomycin, ST = short-term, .